⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Peripheral artery disease (PAD) — the narrowing and hardening of arteries supplying blood to the legs, feet, and lower limbs — affects an estimated 5–7% of Indians with type 2 diabetes, rising to over 20% in those who have had diabetes for more than 10 years. It is a leading cause of diabetic foot complications, non-healing ulcers, and amputation in India. Yet it remains severely underdiagnosed.
Consult your healthcare provider before starting any medication or making changes to your treatment plan.
This guide is for informational purposes only. It does not replace advice from a qualified physician or vascular surgeon.
South Asian Indians develop type 2 diabetes at younger ages and lower BMIs than Western populations. This means the duration of diabetes — and therefore the cumulative damage to blood vessels — is often longer by the time of diagnosis. Combined with:
...Indian T2D patients face a significantly higher PAD burden than epidemiological data from Western countries would suggest.
India performs over 100,000 major lower limb amputations annually. The vast majority are in diabetic patients. Many are preventable with early detection and effective treatment.
GLP-1 medications (semaglutide in Ozempic and Wegovy; tirzepatide in Mounjaro) were not originally designed for vascular disease, but clinical trial data reveals meaningful cardiovascular benefits.
Evidence from landmark trials:
Mechanisms relevant to PAD:
Ask your doctor for an Ankle-Brachial Index (ABI) test — a simple, non-invasive comparison of blood pressure at your ankle versus your arm. This takes 5–10 minutes and costs ₹200–₹500 at most diagnostic centres.
If ABI is unavailable, ask for arterial Doppler ultrasound of lower limbs — available at most sonography centres (₹1,500–₹3,000).
During GLP-1 treatment, expect gradual rather than rapid changes in PAD symptoms:
Do not expect PAD reversal — arterial disease develops over decades and improves slowly.
PAD reduces the margin for error with foot injuries. An ulcer that would heal in days for a healthy person can take months and risk amputation in a patient with PAD and T2D. GLP-1 does not eliminate this risk immediately.
If you notice any non-healing wound on the foot, see a doctor within 24–48 hours, not weeks.
Standard GLP-1 exercise guidance (resistance training 3x/week) needs adjustment for PAD patients.
Supervised walking therapy is the most evidence-based PAD treatment:
This is called intermittent claudication training and clinical trials show it can improve walking distance by 50–200% over 3–6 months.
If claudication prevents effective walking, alternatives include:
PAD patients typically take multiple medications:
Share the complete list of your current medications with your prescribing doctor when starting GLP-1.
The same high-protein, low-glycaemic diet recommended for all GLP-1 users is beneficial for PAD. Specific additions for vascular health:
Expecting GLP-1 to cure PAD quickly. Arterial disease develops over years and improves slowly. Most benefits require 6–18 months of sustained treatment.
Stopping statins or antiplatelet drugs. GLP-1 is additive for cardiovascular protection — it does not replace these medications.
Ignoring a foot wound. PAD patients with even a minor wound should not adopt a "wait and see" approach. Non-healing diabetic foot ulcers progress rapidly.
Exercising through severe pain. Moderate claudication during walking therapy is expected. Rest pain in the foot at night is a medical emergency — see a vascular surgeon immediately.
Neglecting smoking cessation. Smoking is the single most modifiable PAD risk factor. GLP-1 may reduce cravings (some evidence from clinical trials), but active smoking more than counteracts GLP-1's cardiovascular benefits. Prioritise smoking cessation alongside medication.
See a vascular surgeon if:
Good vascular surgery is available at AIIMS (Delhi, Mumbai, Bhubaneswar), PGI Chandigarh, SGPGI Lucknow, and major private hospitals in metro cities. For those in Tier 2–3 cities, telemedicine referral to a vascular surgeon is increasingly available.
Q: Can GLP-1 reverse established PAD? A: GLP-1 does not directly reverse established arterial plaque. However, it can slow progression, reduce symptoms (claudication, cold feet), and substantially reduce the risk of major adverse limb events (amputation, bypass surgery) through improved blood sugar, blood pressure, and weight.
Q: My cardiologist hasn't mentioned GLP-1 for my PAD. Should I ask? A: Yes. Given the SELECT, LEADER, and SUSTAIN-6 cardiovascular outcomes data, many endocrinologists now recommend GLP-1 for patients with established cardiovascular disease including PAD, even without type 2 diabetes if BMI qualifies.
Q: Which GLP-1 medication is best for PAD? A: The strongest long-term cardiovascular outcomes data is for semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda). Tirzepatide (Mounjaro) shows excellent metabolic results and promising cardiovascular signals but has fewer completed long-term vascular outcomes trials.
Q: My feet are always cold and painful at night. Will GLP-1 help? A: Cold feet in PAD reflects reduced blood flow — GLP-1 can gradually improve this over 6–12 months of treatment as blood sugar and weight improve. However, severe rest pain at night (especially one-sided) warrants urgent vascular assessment, not watchful waiting.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any medication.
